Moomoo AI 已提取核心信息
Burning Rock Biotech Limited, a precision oncology company utilizing next generation sequencing technology, announced on January 4, 2024, that it received a notification from NASDAQ on December 29, 2023, regarding non-compliance with the minimum bid price requirement. For 30 consecutive business days, the closing bid price of the company's American depositary shares (ADSs) was below the required $1.00 per share. The NASDAQ notice does not currently affect the trading of Burning Rock's securities. The company has until June 26, 2024, to regain compliance with the minimum bid price rule, which can be achieved if its closing bid price reaches $1.00 for at least 10 consecutive business days during this period. If compliance is not met by the deadline, Burning Rock may be granted an additional 180 days to meet the requirement. The company's operations remain unaffected by this notice, and it plans to take reasonable measures to regain compliance. Burning Rock's business includes NGS-based therapy selection testing for late-stage cancer patients and NGS-based cancer early detection, which is in the clinical validation stage.
Burning Rock Biotech Limited, a precision oncology company utilizing next generation sequencing technology, announced on January 4, 2024, that it received a notification from NASDAQ on December 29, 2023, regarding non-compliance with the minimum bid price requirement. For 30 consecutive business days, the closing bid price of the company's American depositary shares (ADSs) was below the required $1.00 per share. The NASDAQ notice does not currently affect the trading of Burning Rock's securities. The company has until June 26, 2024, to regain compliance with the minimum bid price rule, which can be achieved if its closing bid price reaches $1.00 for at least 10 consecutive business days during this period. If compliance is not met by the deadline, Burning Rock may be granted an additional 180 days to meet the requirement. The company's operations remain unaffected by this notice, and it plans to take reasonable measures to regain compliance. Burning Rock's business includes NGS-based therapy selection testing for late-stage cancer patients and NGS-based cancer early detection, which is in the clinical validation stage.
使用下一代测序技术的精准肿瘤学公司Burning Rock Biotech Limited于2024年1月4日宣布，它于2023年12月29日收到纳斯达克关于未遵守最低出价要求的通知。连续30个工作日，该公司美国存托股票（ADS）的收盘价低于所需的每股1.00美元。纳斯达克的通知目前并未影响Burning Rock证券的交易。该公司必须在2024年6月26日之前重新遵守最低出价规则，如果在此期间至少连续10个工作日的收盘出价达到1.00美元，则可以实现最低出价规则。如果在截止日期前未达到合规要求，Burning Rock可以再获得180天的时间来满足要求。该公司的运营不受本通知的影响，并计划采取合理措施恢复合规性。Burning Rock的业务包括针对晚期癌症患者的基于NGS的疗法选择测试和基于NGS的癌症早期检测，后者处于临床验证阶段。
使用下一代测序技术的精准肿瘤学公司Burning Rock Biotech Limited于2024年1月4日宣布，它于2023年12月29日收到纳斯达克关于未遵守最低出价要求的通知。连续30个工作日，该公司美国存托股票（ADS）的收盘价低于所需的每股1.00美元。纳斯达克的通知目前并未影响Burning Rock证券的交易。该公司必须在2024年6月26日之前重新遵守最低出价规则，如果在此期间至少连续10个工作日的收盘出价达到1.00美元，则可以实现最低出价规则。如果在截止日期前未达到合规要求，Burning Rock可以再获得180天的时间来满足要求。该公司的运营不受本通知的影响，并计划采取合理措施恢复合规性。Burning Rock的业务包括针对晚期癌症患者的基于NGS的疗法选择测试和基于NGS的癌症早期检测，后者处于临床验证阶段。
有用
没用